1 min read
Add as a preferred source on GoogleGoldman Sachs Upgrades Rocket Pharmaceuticals to Neutral on Danon Disease Therapy
The bank raised its rating from Sell after updates on RP-A501, Rocket Pharmaceuticals’ experimental treatment for the rare disorder Danon disease.
Goldman Sachs upgraded Rocket Pharmaceuticals (RCKT) to Neutral from Sell after recent updates involving RP-A501, the company’s experimental therapy for Danon disease.
Rocket Pharmaceuticals shares rose in afternoon trading Thursday, Oct. 8, following the rating change.
RP-A501 is being developed for Danon disease, a rare disorder. Rocket Pharmaceuticals is a gene therapy developer.
Enna Lee
ReporterEnna Lee reports on investing and digital-asset markets for TokenPost. Send corrections or tips to info@tokenpost.com.